If you got an email from FMCSA this week telling you to prepare for Motus, you might have rolled your eyes. Another promise ...
Belite Bio has said the results of the DRAGON trial of its oral therapy for sight-robbing disorder Stargardt disease type 1 (STGD1), tinlarebant, could support an FDA filing. The San Diego biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results